Table 2.
Cardiovascular risk markers among 60 CHC patients and 60 matched HCV-uninfected controls
| CHC patients
|
HCV-uninfected
|
PR (95% CI) | |
|---|---|---|---|
| Count (%) | Count (%) | ||
| Increased CIMTa | 5 (8.6) | 2 (3.3) | 1.67 (0.42–6.66) |
| Increased hsCRP (>2 mg/mL) | 32 (53.3) | 27 (45.0) | 1.19 (0.82–1.71) |
| Metabolic syndrome | 17 (28.3) | 11 (18.3) | 1.55 (0.79–3.02) |
| Mean (SD) | Mean (SD) | Difference of means (95% CI) | |
|
| |||
| CIMT (mm) | 0.66 (0.11) | 0.62 (0.11) | 0.04 (0.00–0.08) |
| hsCRP (mg/mL) | 7.15 (16.2) | 3.74 (5.1) | 3.41 (−0.98–7.80) |
| sICAM-1 (ng/mL) | 248.3 (137.3) | 125.5 (47.7) | 122.87 (85.53–160.20) |
| sVCAM-1 (ng/mL) | 1440.8 (509.0) | 1103.6 (180.1) | 337.20 (198.5–475.89) |
| s-E-selectin (ng/mL) | 65.6 (41.8) | 23.4 (13.9) | 42.25 (30.93–53.58) |
| tPAI-1 (ng/mL) | 57.3 (31.2) | 72.8 (37.6) | −15.52 (−27.98 to −3.06) |
| MMP9 (ng/mL) | 65.4 (46.8) | 91.2 (46.7) | −25.82 (−42.70 to −8.94) |
| MPO (ng/mL) | 41.1 (99.5) | 94.0 (129.0) | −52.83 (−94.32 to −11.34) |
Note:
a
Age- and sex-dependent, see text for explanation.
Abbreviations: CHC, chronic hepatitis C; CIMT, carotid intima media thickness; HCV, hepatitis C virus; hsCRP, high-sensitivity C-reactive protein; MMP9, matrix-metallopeptidase 9; MPO, myeloperoxidase; PR, prevalence ratio; SD, standard deviation; s-E-selectin, soluble E-selectin; sICAM-1, soluble intercellular adhesion molecule 1; sVCAM-1, soluble vascular adhesion molecule 1; tPAI-1, tissue-type plasminogen activator inhibitor; CI, confidence interval.